Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$518 Mln
P/E Ratio
--
P/B Ratio
0.68
Industry P/E
--
Debt to Equity
0.01
ROE
-0.29 %
ROCE
-27.87 %
Div. Yield
0 %
Book Value
13.67
EPS
-2.91
CFO
$-246.73 Mln
EBITDA
$-458.73 Mln
Net Profit
$-493.47 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bicycle Therapeutics - ADR
| -47.21 | -23.74 | -45.62 | -66.30 | -32.48 | -12.76 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Bicycle Therapeutics - ADR
| -22.40 | -38.92 | -51.37 | 239.11 | 90.35 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include... zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Address: Portway Building, Cambridge, United Kingdom, CB21 6GS Read more
CEO & Executive Director
Dr. Kevin Lee M.B.A., Ph.D.
CEO & Executive Director
Dr. Kevin Lee M.B.A., Ph.D.
Headquarters
Cambridge
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bicycle Therapeutics plc - ADR stood at $ 957 Mln as on 31-Dec-24
The share price of Bicycle Therapeutics plc - ADR is $7.39 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Bicycle Therapeutics plc - ADR has given a return of -32.48% in the last 3 years.
Bicycle Therapeutics plc - ADR has a market capitalisation of $ 518 Mln as on 17-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Bicycle Therapeutics plc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bicycle Therapeutics plc - ADR and enter the required number of quantities and click on buy to purchase the shares of Bicycle Therapeutics plc - ADR.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Address: Portway Building, Cambridge, United Kingdom, CB21 6GS
The CEO & director of Dr. Kevin Lee M.B.A., Ph.D.. is Bicycle Therapeutics plc - ADR, and CFO & Sr. VP is Dr. Kevin Lee M.B.A., Ph.D..
There is no promoter pledging in Bicycle Therapeutics plc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Bicycle Therapeutics plc - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-29.04
|
|
Operating margin(%)
|
-487.78
|
|
Net Margin(%)
|
-479.18
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bicycle Therapeutics plc - ADR was $0 Mln.
$-0.10
(
